» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien
Alle Linien
AMG 510_20170543 A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100) (Aktiv)
ATRi_Bay–Studie Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (Aktiv)
BI 907828 This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (Aktiv)
CONKO-011 Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)
CodeBreak 101 A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (Aktiv)
IMbrella B An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) (Aktiv)
LIBERAL Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)
LIBRETTO-201 Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (Aktiv)
MAESTRO Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)
MASTERKEY-318 This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. (Aktiv)
MK-3475-587 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)
MR Linac Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)
NEPO_MUC Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)
NOA-26 - IT-PD1 Intrathekale Anwendung von PD1-Antikörpern bei metastasierten soliden Tumoren mit leptomeningealer Erkrankung (Aktiv)
ROSETTA RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)
SIP (CHAI) Simultane integrierte Protektion zur Schonung der kritischen Organe in der Nähe von Läsionen bei der Körperstereotaxie (Aktiv)
SPIN-MET, SPIME2013 Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)
SenPET Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)
Erstlinie
BrigaPed A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors (Aktiv)
Keynote-158, MK3475-158 Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)
LCNEC-ALPINE A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)
Zweitlinie oder später
213406 A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours (Aktiv)
AFM24-101 A Phase 1/2a Open Label, Multicenter Study to Access the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients With Advanced Solid Tumors (Aktiv)
AMG305_20220073 Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (Aktiv)
Amgen 20210023 Eine Phase-1/1b/2-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von AMG 193 allein und in Kombination mit Docetaxel bei Patienten mit fortgeschrittenen soliden MTAP-null-Tumoren (Aktiv)
BI 1403-0002 Eine offene Phase-Ia/Ib-Dosis-Eskalationsstudie zur Kombination von BI 907828 mit BI 754091 (Ezabenlimab), gefolgt von Erweiterungskohorten, bei Patienten mit fortgeschrittenen soliden Tumoren (Aktiv)
BI 1479-0001 An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations (Aktiv)
BMS CA052-002 A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors (Aktiv)
BNT211-01 A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)
BoB Module 1 A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)
CA030-001 An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)
CHORDOM (HIT-1 / CH.P.12C) Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)
CINC280A2X02B Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment as monotherapy or in combination treatment (Aktiv)
CLDK378A2407 study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CNIZ985B1201 A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab (Aktiv)
CatalYm CTL-002-001 First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)
DLL3 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)
I3Y-MC-JPCS Abemaciclib A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors (Aktiv)
ICT01-102 (EVICTION-2) A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors. (EVICTION-2) (Aktiv)
IGNYTE (RPL-001-16) Eine offene, multizentrische Phase-1/2-Studie mit RP1 als Einzelwirkstoff und in Kombination mit PD1-Blockade bei Patienten mit soliden Tumoren (Aktiv)
IMA 201-101 TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (Aktiv)
IMA 401-101 A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)
IMA402 (bispecific T cell engaging receptor molecule) A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors (Aktiv)
INFORM2-NivEnt (NCT-2017-0516) INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)
INSIGHT Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)
IRON-2 Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases (Aktiv)
KontRASt-01 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (Aktiv)
KontRASt-03 A Phase Ib/II, multicenter, open-label dose escalation and expansion platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation (Aktiv)
LIBRETTO-001 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)
LOXO-TRK-15003 A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)
MCLA-128-CL01/MERUS A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)
MK-3475 Study of Pembrolizumab (MK-3475) in Children (Aktiv)
MK-7684A-005 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)
MK7339-007 Eine Phase-2-Studie mit Pembrolizumab in Kombination mit Olaparib bei Teilnehmern mit vorbehandeltem, Homologe Rekombinationsreparatur-Mutation (HRRm) oder Homologe Rekombinationsdefizienz (HRD) positivem fortgeschrittenem Krebs (Aktiv)
NCT-2017-0417 Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The primary objective is to show superior disease control rate in patients with HRR-deficient tumors treated with olaparib and trabectedin compared to treatment according to current guidelines (physician's choice) (Aktiv)
Olaparib / AstraZeneca A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours (Aktiv)
Proto-R-Kinder Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)
SATURNUS Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)
SGNPDL1V-001 A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)
STARTRK-NG A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (Aktiv)
STARVATION Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)
TAPISTRY Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (Aktiv)
TKnife TK-8001 A Phase 1/2, First-in-Human, Open-Label, Two Part Clinical Trial of TK-8001 (MAGE-A1--Directed TCR Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy (Aktiv)
VB N-02 Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (Aktiv)